The National Institute for Health and Care Excellence has published a new draft guideline on polyendocrine metabolic ovarian syndrome, or PMOS, describing it as the first guideline on the condition tailored to a UK population and recommending annual review to improve diagnosis and care.
The draft, published on July 1, 2026, is intended to help people with PMOS be diagnosed earlier and receive evidence-based support from healthcare professionals from the outset. NICE says the condition is comprehensively addressed in the guidance and that the recommendations also signpost related advice on cardiovascular disease and diabetes, two conditions linked to increased risk in people with PMOS. NICE draft guideline
Why the draft matters for patients and clinicians
According to NICE, the guideline is designed to reduce the delays and uncertainty that can surround PMOS diagnosis, while setting a clearer standard for follow-up care. The recommendation for annual review is positioned as a practical step to ensure people with the condition are monitored consistently and supported across the wider range of health issues associated with PMOS.
The organisation also highlights the importance of a UK-specific approach. By tailoring the draft to a UK population, NICE says the document is meant to reflect how care is delivered within the NHS and provide clinicians with a more relevant framework for assessment and ongoing management.
What happens next
The draft guideline is currently open for consultation, meaning comments can still shape the final version before publication. NICE has not indicated in the source material that the recommendations are final, but the draft already signals the direction of future practice: earlier recognition, annual follow-up and clearer links to related condition guidance.
For people living with PMOS, the development is likely to be seen as a significant step toward more consistent care. For clinicians, it offers a clearer pathway for review and referral, as well as a reminder that PMOS may carry broader cardiometabolic risks that should not be overlooked.
As the consultation process continues, attention will now turn to whether the final guidance keeps the same emphasis on early diagnosis and routine annual review, or whether the recommendations are refined further before adoption.
